A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan; Shanmugapriya Thangavadivel; David M. Weiss; Lai Wei; Jennifer A. Woyach; Kerry A. Rogers; Jeffrey A. Jones; Leslie A. Andritsos; Natarajan Muthusamy; Barbara L. Andersen

doi:10.1182/blood.v130.suppl_1.1748.1748

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Identifier:nobleid.org/w1/20260515/75CD50CC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/75CD50CC.svg?ark=w1%2F20260515%2F75CD50CC)](https://nobleid.org/work/w1/20260515/75CD50CC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Farrukh T. Awan

Shanmugapriya Thangavadivel

Claim authorship of this work

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Identifier:nobleid.org/w1/20260515/75CD50CC

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/75CD50CC.svg?ark=w1%2F20260515%2F75CD50CC)](https://nobleid.org/work/w1/20260515/75CD50CC)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Farrukh T. Awan

Shanmugapriya Thangavadivel

Claim authorship of this work